12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Simeprevir: Phase III data

The double-blind, international Phase III QUEST-1 trial in 394 treatment-naive patients with HCV genotype 1 infection showed that once-daily 150 mg oral simeprevir for 12 weeks plus Pegasys peginterferon alfa-2a and Copegus ribavirin for 24 or 48 weeks (n=264) met the primary endpoint of a greater proportion of patients achieving an SVR defined as undetectable HCV RNA levels (<25 IU/mL)...

Read the full 300 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >